Induced Pluripotent Stem Cells Generated Using Lentivirus-based Reprogramming


Five human induced pluripotent stem cells (iPSC) lines are generated using lentivirus-based reprogramming technology. These lines are pluripotent, meaning they have the potential to differentiate into all cells in the body, and theoretically can proliferate/self-renew indefinitely. The iPSC lines are: NC1 (derived from female's fibroblasts), NC2 (derived from female's fibroblasts ), NC3 (derived from male's HUVECS), NC4 (derived from male's fibroblasts) and NC5 (derived from female's fibroblasts). Further details of these cells are available upon request. NC1 uses a retrovirus delivery system incorporating the following vectors: pMIG-hKLF4, pMIG-hOCT4, pMIG-hSOX2, and MSCV h c-MYC IRES GFP. NC2-NC5 use the hSTEMCCA-loxP lentivirus delivery system (a gift from Dr. Gustavo Mostoslavsky). These cell lines will be useful for studies related to stem cell biology, understanding diseases, potential cell therapies, and small molecule screening.

Potential Commercial Applications: Competitive Advantages:
The iPSCs of this technology are useful:
  • to study the biology of stem cell development
  • as controls in studies to screen for small molecules to change cell fate and/or to alleviate the phenotypes of various diseases
  • to test different characterization and differentiation assays
 
  • These cells can serve as control cells and, thus, significantly reduce the cost of initiating many research projects.
  • These cells can be a good source of control cells.


Development Stage:
  • Prototype
  • Pilot
  • Early-stage
  • In vitro data available


Inventors:

Manfred Boehm (NHLBI)  ➽ more inventions...

Guibin Chen (NHLBI)  ➽ more inventions...


Intellectual Property:
Research Tools – Patent protection is not being pursued for this technology.

Collaboration Opportunity:

The National Heart, Lung, and Blood Institute is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize Induced Pluripotent Stem Cells. For collaboration opportunities, please contact Denise Crooks at 301-435-0103.


Licensing Contact:
Michael Shmilovich, J.D.
Email: shmilovm@mail.nih.gov
Phone: 301-435-5019

OTT Reference No: E-274-2012-0
Updated: May 7, 2013